SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares in an open-market transaction at a weighted average price of $4.5421 per share. The sale was executed under a pre-established Rule 10b5-1(c) trading plan, and Xu held 626,888 shares directly after the transaction.
SOPHiA GENETICS SA director Kathy L. Hibbs reported an open-market sale of 7,508 Ordinary Shares on May 12, 2026. The shares were sold at a weighted average price of $4.6666 per share, in multiple trades between $4.54 and $4.85.
The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Hibbs directly owns 89,768 Ordinary Shares. This represents a partial reduction of her holdings while retaining a substantial remaining position in the company.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on May 12, 2026 at a weighted average price of $4.6689 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan, and Menu now holds 256,388 shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 ordinary shares in an open-market transaction. The sale took place at a weighted average price of $5.0872 per share under a duly adopted Rule 10b5-1(c) trading plan. Following this transaction, he reports direct ownership of 3,633,981 ordinary shares.
SOPHiA GENETICS SA has called its 2026 Annual General Meeting for June 18, 2026 in Rolle, Switzerland, asking shareholders to approve 2025 financial statements, compensation budgets and an increase in conditional share capital. The Board also proposes amending the articles to allow up to 24,807,564 conditional shares for employee participation.
In 2025, the company generated IFRS revenue of $77.3 million, up 19% year over year, but recorded an IFRS net loss of $79.0 million and adjusted EBITDA of –$41.5 million. Adjusted gross margin was 74.2%, and the accumulated deficit to be carried forward totals CHF 403.8 million.
The letter highlights 391,000 platform analyses in 2025 (over 2.3 million since inception), 993 customers and net dollar retention rising to 115% with churn below 1%. Founder Dr. Jurgi Camblong plans to transition to Executive Chair (subject to election), while President Ross Muken becomes CEO effective July 1, 2026.
SOPHiA GENETICS reported higher Q1 2026 revenue but remained loss-making. Revenue reached $21.7 million, up 22% year over year, driven mainly by SOPHiA DDM Platform usage. Gross margin stayed strong at 68%. The company posted a net loss of $19.3 million, or $(0.27) per share.
Cash and cash equivalents were $65.4 million with borrowings of $47.8 million. SOPHiA raised $14.5 million via an at-the-market share program. Platform analysis volume grew 16% to 107,576, Core Genomics Customers increased to 537, and net dollar retention reached 117%, reflecting greater spending by existing customers.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu executed an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.8178 per share. Following this transaction, he directly holds 261,388 Ordinary Shares. The sale was made under a duly adopted Rule 10b5-1(c) trading plan.
SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 380 ordinary shares in an open-market transaction. The shares were sold at a weighted average price of $5.2031 per share on April 20, 2026, and she held 215,071 shares afterward.
According to the disclosure, the sale was made solely to cover tax withholding obligations tied to restricted stock units that vested on April 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary market-timing trades.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $5.2053 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.
The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. Following these sales, Xu directly holds 630,888 Ordinary Shares.
SOPHiA GENETICS SA Chief Legal Officer Van Well Daan sold 684 Ordinary Shares in an open-market transaction at a weighted average price of $5.1963 per share. The sale occurred on April 20, 2026 and was executed to cover tax withholding obligations from restricted stock units that vested on April 18, 2026.
The filing states that these transactions were carried out under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Van Well Daan directly owned 345,736 Ordinary Shares.